Výsledky vyhledávání - "Manuel Philco"

Akademický článek

Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

Autor: Shore, Neal D., Fizazi, Karim, Tammela, Teuvo L.J., Luz, Murilo, Salas, Manuel Philco, Ouellette, Paul, Jr., Lago, Sérgio, Bastos, Diogo Assed, Jansz, G. Kenneth, Cárcano, Flavio Mavignier, Andrade, Lívia, Pliskin, Marc, Lazaretti, Nicolas, Arruda, Larissa, Correa Ochoa, José Jaime, Kuss, Iris, Kappeler, Christian, Sarapohja, Toni, Smith, Matthew

Publikováno v: In European Journal of Cancer December 2023 195

Zobrazit plný text záznamu

Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A

Autor: Manuel Philco, Carlos Barrios, Heather Hinton, Igor Bondarenko, Shigehira Saji, Nicholas C. Turner, Ruffo Freitas-Junior, Qinshu Lian, Matthew Wongchenko, Denise Bradley, Rebecca Dent, Aruna Mani, Joyce O'Shaughnessy, Steven J. Isakoff, Sung-Bae Kim, Mafalda Oliveira

Publikováno v: Cancer Research. 81:GS3-04

Background: In the randomized phase II LOTUS trial [Kim, Lancet Oncol 2017], adding IPAT to PAC improved progression-free survival (PFS), with a more pronounced effect in patients with PIK3CA/AKT1/PTEN-altered tumors. This effect provided the rationa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3c477b0f22f5496e0755fbe785d3020
https://doi.org/10.1158/1538-7445.sabcs20-gs3-04

Zobrazit plný text záznamu

Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST)

Autor: Q. Zhang, Xiao Li, Magalie Hilton, Eric C. Anderson, Gaurav Pathria, M. Mathisen, Aleksandra Szczesna, Zhen Shi, Rafal Dziadziuszko, Luis Corrales-Rodriguez, Vijay Bhagawati-Prasad, Parneet Cheema, Alona Zer, Sarah M. Paul, Manuel Philco

Publikováno v: Journal of Clinical Oncology. 39:9023-9023

9023 Background: BFAST (NCT03178552) is a global, multicohort trial of targeted therapies or cancer immunotherapy (CIT) in treatment (tx)-naive aNSCLC. Pts are screened for the study using comprehensive blood-based next-generation sequencing (NGS). I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05ad61d60cc8a2bc9c920a2f71337738
https://doi.org/10.1200/jco.2021.39.15_suppl.9023

Zobrazit plný text záznamu

Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial

Autor: G. Kenneth Jansz, Neal D. Shore, Paul Ouellette, Flavio Mavignier Carcano, Matthew R. Smith, Christian Kappeler, Sergio Lago, Manuel Philco Salas, Toni Sarapohja, Teuvo L.J. Tammela, Jose Jaime Correa, Larissa De Arruda, Nicolas Lazaretti, Karim Fizazi, Murilo Luz, Marc Pliskin, Oana Petrenciuc, Diogo Assed Bastos, Livia Andrade

Publikováno v: Journal of Clinical Oncology. 39:240-240

240 Background: DARO is a structurally distinct androgen receptor inhibitor approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) based on significantly prolonged metastasis-free survival compared with PBO (median

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56b8ccb913aa851caa08f6bd4e1b9fc4
https://doi.org/10.1200/jco.2021.39.6_suppl.240

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Autor: Henry L. Gomez, M. Conlan, Rafael D. Escandon, Manuel Philco, Patricia Pimentel, Miriam Kiyan, Andrew A. Wolff, J. Seroogy, Maria Laura Monsalvo, Khalil G. Saikali, Michael M. Chen

Publikováno v: Anti-cancer drugs. 23(3)

The objective of the study was to evaluate the safety, pharmacokinetics, and antitumor activity of ispinesib, a kinesin spindle protein inhibitor. Patients with locally advanced or metastatic breast cancer who had received only prior neoadjuvant or a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875fd20b8f41bb74e98d1c770a1f040a
https://pubmed.ncbi.nlm.nih.gov/22123335

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabine and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study

Autor: Eric Van Cutsem, Manuel Philco, Anthony R. Pritchard, Mikhail Lichinitser, Yoon-Koo Kang, Akira Sawaki, Yung-Jue Bang, Brad L. Stanford, N. Al-Sakaff, Lin Shen, Harald A. Weber

Publikováno v: Gastroenterology. 140:S-204

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::820cadca5d1b87f141ba792f94c764dc
https://doi.org/10.1016/s0016-5085(11)60824-x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání